Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

biomarker Driven Strategies for Targeted Elimination of Hypoxia Adapted Lymphoma Cells

Pavel Klener, Jr., Lenka Daumová, Dmitry Kazantsev, Ladislav Anděra, Jiří Petrák, Alexandra Dolníková, Nardjas Bettazová, Petra Kovaříková, Nicol Renešová, Liliana Tušková, Dana Sovilj, Marek Trněný, Magdalena Klanova, Ondrej Havránek

Blood (2023) 142 (Supplement 1): 4374.

https://doi.org/10.1182/blood-2023-182705

Published: 2023

Journal Articles

Single Cell RNA Sequencing Enables Identification of Mantle Cell Lymphoma Subclones with Drug-Resistant Profiles Already at Diagnosis and May be Used for Therapy Prognostication and Personalization

Dmitry Kazantsev, Magdalena Klanova, Michal Kolář, Robert Ivánek, Marek Trněný, Pavel Klener, Jr.

Blood (2023) 142 (Supplement 1): 3004.

https://doi.org/10.1182/blood-2023-185925

Published: 2023

Journal Articles

How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?

Prokop Vodicka, Katerina Benesova, Andrea Janikova, David Belada, Heidi Mocikova, Jan Pirnos, Vit Prochazka, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Petra Blahovcova, Vit Campr, Pavel Klener, Jr., Alice Sykorova, Marek Trneny

Blood (2022) 140 (Supplement 1): 3775–3776.

https://doi.org/10.1182/blood-2022-159408

Published: 2022

Journal Articles

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/Refractory Mantle Cell Lymphoma

Diana Malarikova, Radek Jorda, Alexandra Dolníková, Ondrej Havranek, Eva Pokorna, Dmitry Kazantsev, Dana Sovilj, Karel Helman, Magdalena Klanova, Ladislav Andera, Miroslav Strnad, David Chiron, Marek Trneny, Pavel Klener, Jr.

Blood (2022) 140 (Supplement 1): 5996–5997.

https://doi.org/10.1182/blood-2022-168617

Published: 2022

Journal Articles

BCL-XL Blockage with A1155463 Significantly Increases Efficacy of Venetoclax in Mantle Cell Lymphoma in Vitro and In Vivo

Alexandra Dolníková, Dmitry Kazantsev, Diana Malarikova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Ladislav Andera, Marek Trněný, Pavel Klener, Jr.

Blood (2022) 140 (Supplement 1): 6383–6384.

https://doi.org/10.1182/blood-2022-170109

Published: 2022

Journal Articles

Inhibition of MAPK-ERK Signaling Pathway Overcomes Microrna-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma

Olga Kersy, Mali Salmon-Divon, Maria Gomes da Silva, Ana Filipa Moita, Jose Cabecadas, Pavel Klener, Jr., Marek Trněný, May Basood, Ofer Shpilberg, Oshrat Hershkovitz-Rokah

Blood (2022) 140 (Supplement 1): 3109–3110.

https://doi.org/10.1182/blood-2022-169574

Published: 2022

Journal Articles

Sequencing-Based Analysis of Clonal Evolution of 25 Mantle Cell Lymphoma Patients at Diagnosis and after Failure of Standard Immunochemotherapy

Jana Karolova, Dmitry Kazantsev, Michael Svaton, Liliana Tušková, Kristina Forsterova, Diana Malarikova, Katerina Benesova, Tomáš Heizer, Alexandra Dolníková, Magdalena Klanova, Eva Fronkova, Marek Trněný, Pavel Klener, Jr.

Blood (2022) 140 (Supplement 1): 6409–6410.

https://doi.org/10.1182/blood-2022-166069

Published: 2022

Journal Articles

Combination Benefit of Capivasertib and Venetoclax in Preclinical Models of Diffuse Large B-Cell Lymphoma

Brandon Willis, India Neveras, Hannah Dry, Wendan Xu, Yang Li, Kevin Mongeon, Justine Roderick, Alan Rosen, Pavel Klener, Jr., Georg Lenz, Jerome Mettetal, Simon Barry

Blood (2021) 138 (Supplement 1): 1870.

https://doi.org/10.1182/blood-2021-153711

Published: 2021

Journal Articles

Ibrutinib in Mantle Cell Lymphoma Patients: Analysis of the Czech Lymphoma Study Group

Aleš Obr, Pavel Klener, Jr., Andrea Janíková, Heidi Mocikova, David Belada, David Šálek, Alice Sýkorová, Andrea Jirkuvová, Tomáš Papajík, Marek Trněný

Blood (2021) 138 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2021-146589

Published: 2021

Journal Articles

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BCL2 Inhibitor Venetoclax in Experimental Models of Chemotherapy Refractory Mantle Cell Lymphoma

Diana Malarikova, Radek Jorda, Alexandra Dolnikova, Eva Pokorna, Dmitry Kazantsev, Ondrej Havranek, Karel Helman, Magdalena Klanova, Miroslav Strnad, Marek Trneny, Pavel Klener, Jr.

Blood (2021) 138 (Supplement 1): 1203.

https://doi.org/10.1182/blood-2021-150517

Published: 2021

Journal Articles

High TP53 Mutation Load Predicts Primary Refractory Mantle Cell Lymphoma

Aleš Obr, MD PhD, Pavel Klener, Jr., Eva Kriegova, Dr, assoc prof, Zuzana Zemanova, PhD, Helena Urbankova, MSc, PhD, Andrea Jirkuvova, MD, Anna Petrackova, MSc, Barbora Cudova, Lenka Sedlarikova, MSc, VIT K Prochazka, MD, Tomas Papajik, MD prof, Marek Trneny, MD prof

Blood (2019) 134 (Supplement_1): 3995.

https://doi.org/10.1182/blood-2019-123812

Published: 2019

Journal Articles

Co-Targeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Refractory Mantle Cell Lymphoma with Complex Karyotype Changes

Pavel Klener, Jr., Marek Trněný, Ladislav Andera, MSc, PhD, Zuzana Nahacka, MSc, Magdalena Klanova, MD PhD, Jana Karolova, MD, Michael Svaton, MD, Ondrej Havranek, MDPhD, Jan Soukup, MD, Zuzana Zemanova, PhD, Diana Tuskova, MD, Eva Pokorna, Kristina Forsterova, MSc, PhD, Petra Vockova, MD, Eva Fronkova, MD PhD, Dana Prukova, Ing, PhD

Blood (2018) 132 (Supplement 1): 42.

https://doi.org/10.1182/blood-2018-99-112437

Published: 2018

Journal Articles

Role of Angiogenesis and Anti-Angiogenic Treatment Strategies in Mantle Cell Lymphoma

Petra Vockova, MD, Magdalena Klanova, MD PhD, Jan Molinsky, MD PhD, Diana Tuskova, MD, Bokang Calvin Maswabi, MD PhD, Radek Jaksa, MD, Marek Trneny, MD CSc, Pavel Klener, Jr.

Blood (2018) 132 (Supplement 1): 1672.

https://doi.org/10.1182/blood-2018-99-116874

Published: 2018

Journal Articles

Destiny of Elderly Patients with Lymphoma Indicated for Autologous Stem Cell Transplantation (ASCT)

Robert Pytlik, Kamila Polgarova, MD, Marie Trnkova, Mgr, Pavel Klener, Jr., MD PhD Assoc Prof, Petra Blahovcova, Mgr, Blanka Vackova, MD, Eva Konířová, MD, Benešová Kateřina, MD PhD, Marek Trněný, MD PhD

Blood (2017) 130 (Supplement 1): 3289.

https://doi.org/10.1182/blood.V130.Suppl_1.3289.3289

Published: 2017

Journal Articles

Rituximab Maintenance Failure in Mantle Cell Lymphoma Is Associated with High Risk of Death: Analysis of the Czech Lymphoma Study Group (CLSG)

Aleš Obr, MD, Vit Prochazka, MD PhD Assoc Prof, Tomas Papajik, MD PhD prof., Pavel Klener, Jr., MD PhD Assoc Prof, Andrea Janikova, MD PhD Assoc Prof, David Salek, MD PhD, David Belada, MD PhD, Robert Pytlik, Alice Sýkorová, MD PhD, Heidi Mocikova, MD PhD, Martin Simkovic, MD PhD, Vit Campr, MD PhD, Jitka Dlouha, Tomas Fuerst, MSc, PhD, Marek Trněný, MD PhD

Blood (2017) 130 (Supplement 1): 1498.

https://doi.org/10.1182/blood.V130.Suppl_1.1498.1498

Published: 2017

Journal Articles

Downregulation Of Deoxycytidine Kinase In Cytarabine-Resistant Mantle Cell Lymphoma Cells Confers Cross-Resistance To Nucleoside Analogs Fludarabine, Gemcitabine and Cladribine, But Not To Other Classes Of Anti-Lymphoma Agents

Magdalena Klanova, Lucie Lorkova, MSc, Ondrej Vit, MSc, Bokang Maswabi, MD, Jan Molinsky, MD, Jana Pospisilova, MSc, Cory Mavis, BSc, MSc, Francisco Hernandez, MD, Martin Vokurka, MD, PhD, Jiri Petrak, MSc, PhD, Pavel Klener, Jr., MD, PhD

Blood (2013) 122 (21): 3835.

https://doi.org/10.1182/blood.V122.21.3835.3835

Published: 2013

Journal Articles

MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo

Matthew J. Barth, MD, Cory Mavis, BSc, MSc, Natalie M. Czuczman, BSc, Sarah Frys, BSc, Pavel Klener, Jr., MD, PhD, Myron S. Czuczman, MD, Francisco Hernandez-Ilizaliturri, MD

Blood (2013) 122 (21): 647.

https://doi.org/10.1182/blood.V122.21.647.647

Published: 2013

Journal Articles

CD31/PECAM-1 Is Overexpressed On Mantle-Cell Lymphoma (MCL) Primary Cells and Positively Regulates Engraftment and Growth of MCL Cell Lines in Immunodeficient Mice.

Jan Molinsky, MD, Magdalena Klanova, MD, Bokang Maswabi, MD, Josef Karban, MD, Martin Spacek, MD, Marek Trneny, MD, Emanuel Necas, MD, PhD, Jan Zivny, MD, PhD, Pavel Klener, Jr., MD, PhD

Blood (2012) 120 (21): 2681.

https://doi.org/10.1182/blood.V120.21.2681.2681

Published: 2012

Journal Articles

Ublituximab (TGTX-1101), A Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab–resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In vitro and in Vivo models.

John Miller, Matthew J. Barth, MD, Cory Mavis, BSc, MSc, Ping-Chiao Tsai, PhD, Pavel Klener, Jr., MD, PhD, Francisco Hernandez-Ilizaliturri, MD, Myron S. Czuczman, MD

Blood (2012) 120 (21): 2756.

https://doi.org/10.1182/blood.V120.21.2756.2756

Published: 2012

Journal Articles

Ofatumumab (OFA) Is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity in Vitro and in Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models.

Matthew J. Barth, MD, Gopichand Pendurti, MD, Ping-Chiao Tsai, PhD, Cory Mavis, BSc, MSc, Pavel Klener, Jr., Myron S. Czuczman, MD, Francisco Hernandez-Ilizaliturri, MD

Blood (2012) 120 (21): 2757.

https://doi.org/10.1182/blood.V120.21.2757.2757

Published: 2012

NARROW

biomarker Driven Strategies for Targeted Elimination of Hypoxia Adapted Lymphoma Cells

Single Cell RNA Sequencing Enables Identification of Mantle Cell Lymphoma Subclones with Drug-Resistant Profiles Already at Diagnosis and May be Used for Therapy Prognostication and Personalization

How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/Refractory Mantle Cell Lymphoma

BCL-XL Blockage with A1155463 Significantly Increases Efficacy of Venetoclax in Mantle Cell Lymphoma in Vitro and In Vivo

Inhibition of MAPK-ERK Signaling Pathway Overcomes Microrna-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma

Sequencing-Based Analysis of Clonal Evolution of 25 Mantle Cell Lymphoma Patients at Diagnosis and after Failure of Standard Immunochemotherapy

Combination Benefit of Capivasertib and Venetoclax in Preclinical Models of Diffuse Large B-Cell Lymphoma

Ibrutinib in Mantle Cell Lymphoma Patients: Analysis of the Czech Lymphoma Study Group

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BCL2 Inhibitor Venetoclax in Experimental Models of Chemotherapy Refractory Mantle Cell Lymphoma

High TP53 Mutation Load Predicts Primary Refractory Mantle Cell Lymphoma

Co-Targeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Refractory Mantle Cell Lymphoma with Complex Karyotype Changes

Role of Angiogenesis and Anti-Angiogenic Treatment Strategies in Mantle Cell Lymphoma

Destiny of Elderly Patients with Lymphoma Indicated for Autologous Stem Cell Transplantation (ASCT)

Rituximab Maintenance Failure in Mantle Cell Lymphoma Is Associated with High Risk of Death: Analysis of the Czech Lymphoma Study Group (CLSG)

Downregulation Of Deoxycytidine Kinase In Cytarabine-Resistant Mantle Cell Lymphoma Cells Confers Cross-Resistance To Nucleoside Analogs Fludarabine, Gemcitabine and Cladribine, But Not To Other Classes Of Anti-Lymphoma Agents

MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo

CD31/PECAM-1 Is Overexpressed On Mantle-Cell Lymphoma (MCL) Primary Cells and Positively Regulates Engraftment and Growth of MCL Cell Lines in Immunodeficient Mice.

Ublituximab (TGTX-1101), A Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab–resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In vitro and in Vivo models.

Ofatumumab (OFA) Is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity in Vitro and in Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only